Research Signal – Source date 2025-09-16
A treatment strategy that can be directed toward a chosen cell may sound well suited to aging and Alzheimer’s disease. But the brain poses a harder challenge than a blood cancer: some cells may contribute to disease, while nearby neurons are difficult to replace. A review published in September 2025 brings together early experiments on engineered immune cells, from targeting senescent cells in animals to removing amyloid deposits in Alzheimer’s-model mice. It describes possibilities under study, not a treatment shown to help people with Alzheimer’s or extend healthy life.
Why senescent cells attract attention
Some cells stop dividing but remain alive and metabolically active. These senescent cells can release a mixture of signaling molecules known as the senescence-associated secretory phenotype, or SASP. The signals can affect neighboring cells and draw immune cells into the area. Senescent cells also accumulate in tissues with age, and their inflammatory effects are one reason researchers have considered removing them.
The body already has ways to clear damaged or senescent cells. The review describes immune surveillance by cells such as macrophages and T cells, while also noting that senescent cells can increase CD47, a “don’t-eat-me” signal that inhibits macrophage activity. Engineered cells are intended to recognize chosen markers on a target and respond more directly. The idea depends, however, on a marker being present on the intended cells and sufficiently absent from cells that need to remain.
That selectivity is difficult to establish. The review focuses on markers including uPAR and NKG2D ligands, but a single marker or measurement may not accurately identify every senescent cell—or distinguish all of them from healthy cells. A therapy that persists in the body would need especially careful assessment of what else it recognizes and what effects follow.
Animal experiments suggest a route to senescent-cell removal
In animal studies summarized by the review, CAR-T cells—T cells fitted with a chimeric antigen receptor, a synthetic sensor for a chosen target—were directed at uPAR-positive cells. The experiments included senescent cells following cancer-drug treatment, models of liver fibrosis, aged mice, and mice fed a high-fat diet. Reported outcomes included clearance of targeted cells, improvement in fibrosis models, and better metabolic measures such as glucose tolerance in mice.
These are distinct findings in particular animal settings. The metabolic results do not show that the animals lived longer or remained healthier overall, and they do not establish a human anti-aging effect. Separate experiments targeting NKG2D ligands reported senescent-cell elimination in aged mice and nonhuman primates. Those findings extend the evidence beyond a single mouse setting, but they still do not settle long-term safety or show that removing the targeted cells improves health span in people.
Alzheimer’s raises a different targeting problem
In Alzheimer’s disease, a potential target might be an inflammatory immune cell, an amyloid deposit, or a cell with a senescence-like state. Those are different aims, and the appropriate engineered cell may differ for each.
The review describes microglia, the brain’s resident immune cells, as changing with disease progression. In later stages, they can become chronically activated, release inflammatory signals, and fail to clear amyloid effectively. They may also contribute to excessive pruning of synapses, the connections through which neurons communicate. Senescent cells are not evenly distributed across the brain; studies discussed in the review identify particular regions and cell types, including microglia and oligodendrocytes. Neurons can show senescence-like features too, but destroying neurons with amyloid or tau pathology would be hazardous because their capacity to regenerate is limited.
This makes “remove the harmful cells” an incomplete goal. A cell therapy would have to distinguish disease-related targets from neurons and other cells whose function should be preserved. It would also need to reach relevant brain regions without provoking damaging inflammation.
Recognition in cells is not treatment in a brain
One line of work tested whether engineered receptors could recognize forms of amyloid beta and tau in cell systems. Researchers adapted receptors from antibodies used to target these proteins and found that engineered cells responded to corresponding antigens. The cells produced IL-2 when stimulated; their viability also fell when exposed to high concentrations of amyloid beta. These experiments show target recognition and a response in a controlled setting. They do not show that the cells can safely find and act on those targets throughout a human brain.
A different approach uses macrophages, immune cells that can engulf material. In experiments described by the review, researchers equipped macrophages with a receptor based on an antibody to amyloid. The cells resorbed amyloid in laboratory work and brain slices, but their survival in living animals was limited. A reinforced version that produced M-CSF to support its survival resorbed plaques after it was placed directly into the hippocampi of aged Alzheimer’s-model mice.
That is a specific result tied to a particular cell design, mouse model, and local delivery method. It does not establish safe, durable plaque removal across the human brain, and plaque resorption alone is not evidence of improved cognition or patient benefit. Macrophages may offer a different way to engage deposits than antibody-dependent uptake, but the review presents this as an experimental possibility rather than a demonstrated clinical advantage.
The carrier cell changes the risks
CAR-T cells can mount a potent attack, a strength in some cancers that creates concerns in the brain. In cancer treatment, these cells can cause cytokine release syndrome and immune cell-associated neurological syndrome, which can involve language problems, seizures, or brain swelling. In Alzheimer’s, where inflammation and loss of neurons are already concerns, such effects would matter greatly.
Other engineered immune cells could behave differently. CAR macrophages are designed to engulf targets and might be adapted to break down amyloid. Regulatory T cells, or Tregs, restrain immune responses. A CAR-Treg tuned to recognize amyloid or tau could in principle focus that restraint, and engineered Tregs might also be designed to release factors that support neurons. Yet broad immune suppression from non-targeted Tregs carries its own concern, and the proposed targeted strategies remain early research.
Natural killer cells are another candidate. The review notes that they may carry a lower likelihood of cytokine release syndrome than T cells and could be made from cell lines or induced pluripotent stem cells. Their potential for “off-the-shelf” production is an engineering prospect, not evidence that they work for Alzheimer’s. For each cell type, researchers must weigh what it does, how long it persists, and whether its activity can be controlled.
Reaching the brain is part of the treatment
Even a cell with the right target must reach it. The mouse macrophage experiment used placement in the hippocampus, an invasive method that cannot be assumed practical for frail older adults. Giving engineered cells through a vein may not bring enough of them into the relevant brain regions, while a strategy that improves entry or persistence could also change safety.
The review discusses ways researchers are exploring to help cells cross brain blood vessels and remain active, including modifying molecules involved in adhesion or transport across the vessel lining. These are design proposals, not established delivery solutions. Long-lived engineered cells might sustain an effect, but persistence also raises the stakes if a target is misidentified or an immune response becomes harmful. Better delivery therefore has to be considered alongside selectivity and control, rather than as a stand-alone engineering problem.
What targeted immune cleanup could change for Alzheimer’s care
If researchers can reliably identify harmful senescent cells or disease-related material, direct engineered cells to the right brain regions, and protect neurons and healthy tissue, cell therapies could eventually add a targeted way to address inflammation or amyloid in neurodegenerative disease. That could offer a different route from strategies that act throughout the body or rely on antibody-mediated plaque handling. The animal and cell-system findings in the 2025 review make that possibility worth investigating; they do not yet show that people with Alzheimer’s will benefit or that removing senescent cells will extend healthy life.
Key Sources
- Primary source: Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease.
DOI or Journal Page · Review or Meta-Analysis · 2025-09-16
Keep exploring